Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"October 13, 2026 2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on . “
data-action=”subscribe”>
Subscribe
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Key takeaways: Pooled analysis did not confirm superiority of the two-dose HepB-CpG regimen over three doses of aluminum-based vaccines. A third dose of HepB-CpG vaccine may improve immunoprotection among individuals with HIV. NASHVILLE, Tenn. \u2014 Two doses of hepatitis B virus vaccine with CpG adjuvant may not be sufficient for people with HIV who do not respond to an initial vaccination series, according to a poster presentation at ACG Annual Scientific Meeting. Data from pooled analysis did not show statistically significant superiority between two doses of HepB-CpG (Heplisav-B, Dynavax) compared with three doses of HBV vaccine with an aluminum-based adjuvant (Engenrix-B, GSK; Recombivax HB, Merck).
\u201cFor a person with HIV who did not respond to a prior hepatitis B series, HepB-CpG is the preferred revaccination choice over the old alum vaccines, and a third dose is worth considering when durable, high-level protection is the goal,\u201d Mexan Mapouka, MD, MPH, an internal medicine resident at University of Maryland Capital Region Health, told Healio. \u201cThe take-home is not \u2018the vaccines are equal,\u2019 but rather \u2018two doses may not be enough for everyone.\u2019 So check titers and consider a third dose, which lines up with what current HIV and opportunistic-infection guidelines already recommend.\u201d People with HIV are less likely to achieve serologic response to conventional HBV vaccines, according to study background. Two or three doses of HepB-CpG have been recommended for nonresponders in this patient population. However, it remains relatively unknown whether three doses of HepB-CpG, rather than two, provide adequate protection compared with the three doses of the aluminum-based vaccines. \u201cGuidelines now point toward the newer adjuvanted vaccine HepB-CpG for these patients, but they were not settled on whether two doses is enough for prior nonresponders or whether a third dose is needed to match or beat the old three-dose alum vaccines,\u201d Mapouka said. \u201cThe study set out to pool the available data and try to answer that practical, everyday question.\u201d Mapouka and colleagues conducted a systematic and meta-analysis comprised of research published through Jan. 24. Analysis included 493 individuals (mean age, 45 years; 46% white), most of whom were men. The group was balanced in receipt of HepB-CpG (n = 248) and HepB-alum (n = 245) vaccines. Pooled analysis did not show a statistically significant difference in seroconversion with the two-dose HepB-CpG regimen, with no clear superiority observed (RR = 1.35; 95% CI, 0.97-1.87), even with high heterogeneity (I2 = 86.5%). Seroprotection was lower than the 90% threshold among those with diabetes (70.2%) and smokers (84%), according to subgroup analyses. Optimizing CD4 levels could boost HBV antibody response in these subgroups, the researchers noted. \u201cThe most useful future studies would be larger head-to-head trials that enroll more patients with low CD4 counts, who are underrepresented so far; follow antibody titers for several years to measure real durability rather than early response; and look at host factors like diabetes, smoking and inflammation to see who needs an extra dose or other help,\u201d Mapouka told Healio. \u201cMeasuring T-cell responses, not just antibodies, would also add value, since T-cell immunity is impaired in HIV even when antibodies look adequate.\u201d For more information: Mexan Mapouka, MD, MPH, can be reached at mexan.mapouka@umm.edu. Published by: Sources\/Disclosures Source: Mapouka M, et al. Two dose Hep-B-CpG vs three dose HEP-B-Alum among people with HIV and prior vaccine nonresponse: A systematic review and meta-analysis. Presented at: ACG Annual Scientific Meeting; Oct. 12-14, 2026; Nashville, Tenn. (hybrid meeting).
Disclosures:
Mapouka reports no relevant financial disclosures. Please see the study for all other authors\u2019 relevant financial disclosures.
Ask a clinical question and tap into Healio AI’s knowledge base.
PubMed, enrolling\/recruiting trials, guidelines
Clinical Guidance, Healio CME, FDA news
Healio’s exclusive daily news coverage of clinical data
Learn more
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on . “
data-action=”subscribe”>
Subscribe
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Source link<\/p>\n","protected":false},"author":1,"featured_media":4009,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-4008","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/posts\/4008","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4008"}],"version-history":[{"count":0,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/posts\/4008\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/media\/4009"}],"wp:attachment":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4008"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4008"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4008"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"Healio](\"https:\/\/www.healio.com\/~\/media\/h5\/feature\/news\/publogos\/hgld\/healio_gastro.svg?la=en&h=40&w=152&hash=2C654A538F2E250F5183D42A89FE0EC0\")
\n <\/div>\n<\/p><\/div>\n<\/p><\/div>\n